Recent Investment Analysts’ Ratings Changes for Scholar Rock (SRRK)

Several brokerages have updated their recommendations and price targets on shares of Scholar Rock (NASDAQ: SRRK) in the last few weeks:

• 8/21/2026 – Scholar Rock had its “outperform” rating reaffirmed by Wedbush.
• 8/13/2026 – Scholar Rock had its price target raised by JPMorgan Chase & Co. from $56.00 to $63.00. They now have an “overweight” rating on the stock.
• 8/10/2026 – Scholar Rock had its “buy” rating reaffirmed by HC Wainwright. They now have a $65.00 price target on the stock.
• 8/10/2026 – Scholar Rock had its “outperform” rating reaffirmed by Wedbush. They now have a $58.00 price target on the stock.
• 8/7/2026 – Scholar Rock had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $76.00 price target on the stock.
• 8/7/2026 – Scholar Rock had its price target raised by Citigroup Inc. from $58.00 to $60.00. They now have a “buy” rating on the stock.
• 7/21/2026 – Scholar Rock had its “outperform” rating reaffirmed by Wedbush. They now have a $58.00 price target on the stock.
• 7/17/2026 – Scholar Rock had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at Scholar Rock

In related news, Director Michael Gilman sold 2,544 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total value of $137,045.28. Following the sale, the director owned 59,511 shares in the company, valued at $3,205,857.57. This represents a 4.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Katie Peng sold 5,446 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total transaction of $293,430.48. Following the sale, the director directly owned 34,301 shares of the company’s stock, valued at $1,848,137.88. This trade represents a 13.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 17,149 shares of company stock valued at $923,108 over the last three months. 10.30% of the stock is currently owned by corporate insiders.

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).